ADAP News and Press, Adaptimmune Therapeutics plc From 02/18/20

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Gavin Wood as Chief Financial Officer (CFO), effective April 1, 2020. ȁ...

Picking home-run stocks -- or stocks capable of generating exponential returns on capital -- is no easy matter. That being said, there has arguably never been a more favorable environment for risk-tolerant investors on the hunt for unusual growth opportunities.  The fact of the matter is t...

Despite mounting political pressure to drastically lower prescription drug prices in the United States, the biotech industry as a whole has performed quite well during the opening weeks of 2020. The long and short of it is that investors are still fairly optimistic about biotech's long-term pros...

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Adaptimmune Therapeutics (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, has closed an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”). According to the update, Adaptimmune Therapeutics secured gross proceeds of $84 million in the...

Adaptimmune ( ADAP ) announced positive preliminary results using its SPEAR T-cell platform to treat patients with severe different types of solid tumors. These recently released results reinforce prior data in synovial sarcoma and myxoid/round cell liposarcoma ((MRCLS)), and ADP-A2M4 wh...

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its A...

Adaptimmune Therapeutics (NASDAQ: ADAP ) has priced its public offering of 21M American Depositary Shares (“ADSs”) at $4.00 per ADS, for expected gross proceeds of ~$84M. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, Read more...

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depos...